Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosi

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosi
(NASDAQ: MDGL) Delayed: 512.88 +7.13 (1.41%)
Previous Close $505.75    52 Week High $18.24 
Open $513.23    52 Week Low $6.60 
Day High $517.54    P/E N/A 
Day Low $500.80    EPS $0.00 
Volume 281,844       

(NASDAQ: MDGL) Delayed: 512.88 +7.13 (1.41%)
Previous Close $505.75    52 Week High $18.24 
Open $513.23    52 Week Low $6.60 
Day High $517.54    P/E N/A 
Day Low $500.80    EPS $0.00 
Volume 281,844